Dasatinib-d 4

Overview

Dasatinib-d 4 (BMS-354825-d 4 ) is deuterium labeled Dasatinib. Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The K i s are 16 pM and 30 pM for Src and Bcr-Abl , respectively. Dasatinib inhibits Bcr-Abl and Src with IC 50 s of <1.0 nM and 0.5 nM, respectively. Dasatinib also induces apoptosis and autophagy .

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Others | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Autophagy | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Src | Products > Signaling Pathways > Isotope-Labeled Compounds | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Bcr-Abl | Products > Signaling Pathways > Autophagy

Product Information

• Catalog No.: HY-10181S1
• CAS No.: 1160297-08-4
• Molecular Formula: C22H22D4ClN7O2S
• Molecular Weight: 492.03
• Purity: 97.54%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source